Table 2.

Baseline and post-transplant factors associated with developing a CSME

CharacteristicCSME Group (n=23)Non-CSME Group (n=177)P Value
Men11 (48)110 (62)0.19
African-American race7 (30)92 (52)0.05
Highest education level0.13a
 Elementary school0 (0)4 (2.3)
 High school7 (30.4)77 (43.5)
 Some college/technical college9 (39.1)44 (29.9)
 Bachelors degree or higher6 (26.1)36 (20.3)
Primary insurance0.18a
 Medicare20 (87)127 (72)
 Medicaid0 (0)3 (1.7)
 Private3 (13)44 (24.9)
 Tricare0 (0)1 (0.6)
Living donor7 (30)31 (18)0.15
Standard criteria donor14 (61)128 (72)0.26
Diabetes8 (35)55 (31)0.72
Induction therapy with IL-2 receptor antagonist15 (65)83 (47)0.04
Postoperative medications at discharge (n)0.08a
 5–93 (13)31 (18)
 10–1412 (52)96 (54)
 >147 (30)47 (26)
Patient had >2 MEs7 (30)16 (9)<0.01
Patient had >3 MEs4 (17.4)6 (4)<0.01
Post-transplant triazole use7 (30.4)15 (8.5)<0.01
Other drug interactions b4 (17.4)10 (5.6)0.02
Cytopeniasc14 (60.9)67 (37.9)0.03
Nonopportunistic severe infectiond10 (43.5)38 (21.5)0.02
Missed >5 laboratory appointments7 (30)28 (16)0.08
  • Data are n (%) unless otherwise stated. CSME, clinically significant medication error.

  • a Mantel–Haenszel linear-by-linear association chi-squared test (P<0.05).

  • b Other drug interaction: warfarin (75%), amiodarone, or NSAIDs, nonsteroidal anti-inflammatory drug.

  • c Cytopenias include severe leukopenia, anemia, or thrombocytopenia.

  • d Infections include pneumonia, urinary tract infection, or nasopharyngitis.